> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CellTrans BLA Goes Before Advisory Committee
- URL: https://www.fdaweb.com/celltrans-bla-goes-before-advisory-committee/
- Published: 2021-02-17T12:00:00.000Z
- Updated: 2026-09-14T16:47:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148679

*Federal Register* notice: FDA has announced a 4/15 meeting of its Cellular, Tissue and Gene Therapies Advisory Committee. The panel is scheduled to discuss a CellTrans BLA for donislecel (purified allogeneic deceased donor pancreas derived islets of Langerhans), indicated for treating brittle Type 1 diabetes mellitus. The morning session will address issues related to the characterization and critical quality attributes of donislecel as they relate to product comparability in the context of consistent product quality and clinical effectiveness. The afternoon session will discuss results from clinical trials included in the BLA. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-02-17/pdf/2021-03173.pdf?ref=fdaweb.com).